X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs PLETHICO PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS PLETHICO PHARMA IPCA LABS/
PLETHICO PHARMA
 
P/E (TTM) x 36.4 -1.1 - View Chart
P/BV x 3.5 0.0 20,610.9% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   PLETHICO PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
PLETHICO PHARMA
Mar-14
IPCA LABS/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs643395 162.8%   
Low Rs50331 1,606.4%   
Sales per share (Unadj.) Rs254.4604.4 42.1%  
Earnings per share (Unadj.) Rs16.132.5 49.5%  
Cash flow per share (Unadj.) Rs29.851.3 58.0%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.6473.6 41.1%  
Shares outstanding (eoy) m126.2034.08 370.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.30.4 638.7%   
Avg P/E ratio x35.76.6 543.4%  
P/CF ratio (eoy) x19.24.2 463.4%  
Price / Book Value ratio x2.90.5 654.4%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,3007,262 995.5%   
No. of employees `00013.3NA-   
Total wages/salary Rs m6,9601,596 436.1%   
Avg. sales/employee Rs Th2,413.5NM-  
Avg. wages/employee Rs Th523.2NM-  
Avg. net profit/employee Rs Th152.4NM-  
INCOME DATA
Net Sales Rs m32,10620,598 155.9%  
Other income Rs m226386 58.4%   
Total revenues Rs m32,33220,984 154.1%   
Gross profit Rs m4,4482,818 157.9%  
Depreciation Rs m1,730642 269.3%   
Interest Rs m2411,593 15.1%   
Profit before tax Rs m2,703969 279.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m675-138 -487.9%   
Profit after tax Rs m2,0281,107 183.2%  
Gross profit margin %13.913.7 101.3%  
Effective tax rate %25.0-14.3 -174.8%   
Net profit margin %6.35.4 117.5%  
BALANCE SHEET DATA
Current assets Rs m17,34018,877 91.9%   
Current liabilities Rs m9,55911,896 80.4%   
Net working cap to sales %24.233.9 71.5%  
Current ratio x1.81.6 114.3%  
Inventory Days Days10036 279.1%  
Debtors Days Days57198 28.7%  
Net fixed assets Rs m20,7799,861 210.7%   
Share capital Rs m252341 74.1%   
"Free" reserves Rs m24,49912,331 198.7%   
Net worth Rs m24,55316,139 152.1%   
Long term debt Rs m3,5174,706 74.7%   
Total assets Rs m39,59533,146 119.5%  
Interest coverage x12.21.6 760.4%   
Debt to equity ratio x0.10.3 49.1%  
Sales to assets ratio x0.80.6 130.5%   
Return on assets %5.78.1 70.3%  
Return on equity %8.36.9 120.4%  
Return on capital %10.512.3 85.3%  
Exports to sales %48.621.4 227.6%   
Imports to sales %14.215.2 93.5%   
Exports (fob) Rs m15,6174,402 354.7%   
Imports (cif) Rs m4,5713,136 145.8%   
Fx inflow Rs m15,6174,402 354.7%   
Fx outflow Rs m5,8283,184 183.0%   
Net fx Rs m9,7901,219 803.4%   
CASH FLOW
From Operations Rs m2,7642,437 113.4%  
From Investments Rs m-1,432-6,265 22.9%  
From Financial Activity Rs m-1,5912,490 -63.9%  
Net Cashflow Rs m-259-1,337 19.4%  

Share Holding

Indian Promoters % 45.9 82.7 55.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 4.3 265.1%  
FIIs % 25.3 5.5 460.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 7.5 232.0%  
Shareholders   36,892 10,665 345.9%  
Pledged promoter(s) holding % 2.1 85.7 2.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  SUVEN LIFE  

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Rising Oil Prices; RBI Minutes and Top Stocks in Action Today(Pre-Open)

Indian share markets surged on Wednesday, snapping a two-day losing streak led by gains Reliance Industries and bank stocks.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jun 20, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS